摘要
目的 :探讨了血清CA1 2 5、SIL - 2R在卵巢癌诊断和疗效观察中的临床价值。方法 :应用微粒子酶免疫分析法 (MEIA)和酶联吸附法对 36例卵巢癌患者和 5 1例妇科良性肿瘤患者进行了血清CA1 2 5和SIL - 2R水平检测 ,并以 35名正常健康人作对照。结果 :卵巢癌患者血清CA1 2 5、SIL - 2R水平非常显著地高于正常人组(p <0 0 1 ) ,经治疗后三个月血清CA1 2 5、SIL - 2R水平显著下降 ,与正常人组比较 ,无显著性差异 (p >0 0 5 ) ,妇科良性肿瘤组血清与正常人组比较无显著性差异 (p>0 0 5 )。结论 :血清CA1 2 5、SIL - 2R水平检测对卵巢癌的检测具有较高的诊断价值 。
Objective To stud the clinical values of determination of serum CA125 and SIL-2R levels for the diagnosis and therapeatic effect apprasial in patients with ovarian cancer. Methods Serum CA125 levels were determined with MEIA and serum SIL-2R with EIA in 36 patients with ovarian cancer, 51 patients with benign gynecologic tumor as well as 35 controls. Results Serum CA125 and SIL-2R levels were significantly higher in patients with ovarian cancer than those in controls ( p <0 01). Three months after treatmnet there were no significant difference ( p >0 05). Levels in patients with benign gynecologic tumors were about the same as those in controls ( p >0 05). Conclusion Determination of serum CA125 and SIL-2R levels was of great value in the diagnosis, progress monitoring and outcome prediction of ovarian cancer.
出处
《放射免疫学杂志》
CAS
2004年第1期74-75,共2页
Journal of Radioimmanology
